CJC-1295_Ipamorelin is a research peptide used in preclinical laboratory models involving metabolic, mitochondrial, immune, or regenerative pathways.

CJC-1295 (without DAC) + Ipamorelin (IPA) is a dual-peptide research combination developed for investigational and in vitro research use, formulated to study coordinated growth hormone–related signaling pathways. Both peptides are classified as growth hormone–releasing hormone (GHRH) and growth hormone secretagogue pathway modulators, respectively, but operate through distinct receptor mechanisms.

In preclinical and laboratory research models, CJC-1295 (without DAC) has been examined for its interaction with GHRH receptor signaling, while Ipamorelin has been studied for its selective activity at the ghrelin (GHS-R) receptor. As a combined formulation, this pairing is of interest in experimental studies exploring pulsatile growth hormone signaling dynamics, downstream IGF-1 pathway modulation, and anabolic signaling communication under controlled research conditions.

Mechanism of Interest

• GHRH Receptor — CJC-1295 studied as a growth hormone-releasing hormone analog in pituitary cell models.
• Ghrelin Receptor (GHS-R1a) — Ipamorelin investigated as a selective secretagogue receptor ligand.
• Combined Signaling — Examined for the combined effect of both peptides on secretion patterns in vitro.

Key Research Applications

• Growth hormone axis research
• Somatotroph signaling studies
• Peptide combination pharmacology

Research Use Only

This product is supplied strictly for laboratory, research, and development use. Not for human consumption or therapeutic application.